Arlington Capital Management Inc. Invests $211,000 in BioNTech SE (NASDAQ:BNTX)

Arlington Capital Management Inc. acquired a new stake in BioNTech SE (NASDAQ:BNTX) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,000 shares of the company’s stock, valued at approximately $211,000.

Other institutional investors have also recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. grew its position in shares of BioNTech by 3.9% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 3,980 shares of the company’s stock worth $432,000 after buying an additional 148 shares during the period. Raymond James & Associates increased its holdings in BioNTech by 5.6% during the 3rd quarter. Raymond James & Associates now owns 5,579 shares of the company’s stock worth $606,000 after purchasing an additional 298 shares in the last quarter. Mackenzie Financial Corp increased its holdings in BioNTech by 86.5% during the 3rd quarter. Mackenzie Financial Corp now owns 5,131 shares of the company’s stock worth $558,000 after purchasing an additional 2,380 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of BioNTech by 9.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 81,103 shares of the company’s stock valued at $8,811,000 after purchasing an additional 6,682 shares during the period. Finally, Flossbach Von Storch AG lifted its holdings in shares of BioNTech by 2.1% in the third quarter. Flossbach Von Storch AG now owns 3,513,215 shares of the company’s stock valued at $381,676,000 after purchasing an additional 71,468 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Performance

BNTX traded up $1.87 on Thursday, reaching $92.00. The company had a trading volume of 311,662 shares, compared to its average volume of 649,169. The company’s fifty day moving average is $90.47 and its 200 day moving average is $95.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. The stock has a market cap of $21.87 billion, a P/E ratio of 21.88 and a beta of 0.25. BioNTech SE has a fifty-two week low of $85.21 and a fifty-two week high of $125.83.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. As a group, analysts predict that BioNTech SE will post -1.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on BNTX shares. UBS Group cut their target price on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 27th. TD Cowen increased their target price on shares of BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a report on Tuesday. The Goldman Sachs Group reduced their price objective on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 28th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.00 target price on shares of BioNTech in a research report on Thursday, March 21st. Finally, BMO Capital Markets reduced their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $118.82.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.